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DONALD A. CHILSON, MD, JAMES J. HEGER, MD, FACC
Indianapolis, Indiana
Cibenzoline, a new antiarrhythmic agent, was tested in
26 patients who had symptomatic ventricular tachy-
cardia (24 patients) or premature ventricular complexes
(2 patients) unresponsive to conventional drugs. Ciben-
zoline was given orally every 8 hours to maximal doses
of 65 mg in 2 patients, 81.25 mg in 22 patients and 97.5
mg in 2 patients. Cibenzoline abolished spontaneous ep-
isodes of ventricular tachycardia in 8 of 16 patients with
ventricular tachycardia during a 72 hour control electro-
cardiographic recording, and 7 of 22 patients had greater
than 83% decrease in premature ventricular complexes
compared with control. The PR interval increased 14%
(p < 0.001), QRS duration increased 17% (p < 0.001),
QT interval did not change and mean ejection fraction
in 10 patients did not change.
Electrophysiologic studies were performed on 10 pa-
tients in the control period and during maximal ciben-
zoline dosage. Cibenzoline did not affect electrophysio-
logic properties of the atrium or atrioventricular (AV)
node. It prolonged the ventricular effective (223 ± 16
to 241 ± 22 ms, p < 0.02) and functional (247 ± 18 to
Cibenzoline is an imidazoline derivative (4,5-dihydro-2[2,2-
diphenyl-cyclopropyl]-lH-imidazole butanedioate [I: I]) salt
(Fig. I) that is currently undergoing clinical investigation
in the United States as an antiarrhythmic agent. In isolated
rabbit atria, cibenzoline decreased action potential ampli-
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264 ± 25 ms, p < 0.02) refractory periods. At control
electrophysiologic studies, ventricular tachycardia was
induced in 9 of 10 patients (mean cycle length 210 ± 31
ms). Cibenzoline therapy prevented ventricular tachy-
cardia induction in two patients, and in the other seven
patients the mean ventricular tachycardia cycle length
increased from 210 to 260 ms. The one patient with no
ventricular arrhythmia induced during the control study
still had no arrhythmia induced while receiving ciben-
zoline. Among six patients receiving cibenzoline during
follow-up, one patient died of recurrent myocardial in-
farction, two patients stopped taking cibenzoline because
of recurrent ventricular tachycardia and three patients
have continued taking cibenzoline for 10 ± 4 months
with control of symptomatic arrhythmias.
Thus, cibenzoline suppressed ventricular tachycardia
and premature ventricular complexes in some patients
unresponsive to conventional drugs and was well toler-
ated. Cibenzoline significantly prolonged ventricular ef-
fective and functional refractory periods and had min-
imal negative hemodynamic effects.
tude, maximal rate of depolarization and conduction veloc-
ity and prolonged action potential duration (l). In intact
dogs, cibenzoline produced a slight decrease in myocardial
contractility with no effect on blood pressure or myocardial
blood flow (2).
Clinical studies in Europe (2) showed that oral ciben-
zoline was as effective as disopyramide and more effective
than nadoxolol, a beta-adrenergic blocking agent, in sup-
pressing premature ventricular complexes in patients with
chronic arrhythmias, and intravenous cibenzoline was as
effective as intravenous lidocaine in suppression of chronic
premature ventricular complexes but was noted to decrease
left ventricular function more than lidocaine. The purpose
of this study was to investigate the antiarrhythmic, hemo-
dynamic and electrophysiologic effects of cibenzoline in
patients who have symptomatic ventricular arrhythmias un-
responsive to conventional antiarrhythmic drugs.
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Figure 1. Molecular structure of cibenzoline.
Methods
Patients. The study group comprised 20 men and 6 women
whose ages ranged from 29 to 73 years (mean 56 ± 11)
who were being treated for a symptomatic ventricular ar-
rhythmia (Table 1). Each patient had received 2 to 7 (mean
3.3 ± 1.3) trials of antiarrhythmic drugs that were either
ineffective or produced intolerable side effects. Sixteen pa-
tients had coronary artery disease evidenced by a history of
myocardial infarction or the presence of coronary artery
disease by coronary arteriography. Four patients had
congestive cardiomyopathy documented by absence of coro-
Table 1. Patient Population
nary artery disease and presence of a dilated hypokinetic
left ventricle on two-dimensional echocardiography and car-
diac catheterization. Two patients had mitral valve prolapse
documented by echocardiogram and four patients had pri-
mary electrical disease defined as no evidence of heart dis-
ease by clinical examination, echocardiography and cardiac
catheterization. One patient diagnosed as having primary
electrical disease refused coronary catheterization but had
no evidence of heart disease. Each patient gave informed
consent for participation in the study protocol which was
approved by the Committee for Protection of Human Sub-
jects of Indiana University.
Treatment Protocol
At entry a complete history and physical examination
were performed and all antiarrhythmic drugs were discon-
tinued for at least 48 hours. The treatment protocol (Fig.
2) began with a 3 day initial control period during which all
control data were obtained, followed by a treatment phase
in which oral cibenzoline was administered at each dosage
level for 2 day periods.
Arrhythmiat
on Maximal
Age (yr) Heart Clinical Cibenzoline Dose
Case &Sex Disease Arrhythmiat (plasma level ng/ml)
I 53M CAD VF VT-NS
2 71M CAD VT-NS PVC' (344)
3 58M CAD VT-NS VT-NS (690)
4 56M CAD VF VT-NS
5 52M CAD VT-NS VT-S' (519)
6 29F PED PVC-sx PVC' (577)
7 48M MVP VT-NS VT-NS'
8 52M CAD VT-NS PVC' (267)
9 68F CAD VT-S VT-S (413)
10 68M PED PVC-sx PVC'
II 47M CAD VF VF
12 56M PED VF VT-NS
13 52M CAD VT-NS VT-NS
14 58M CM VT-NS VT-NS
15 73F CAD VF VT-NS
16 62M CAD VF VT-NS
17 55M CAD VT-NS VT-S
18 67M CM VF VT-NS
19 40M CAD VT-NS VT-NS
20 58F CAD VT-NS VT-S
21 70M PED VT-S VT-NS
22 48M MVP VT-S VT-NS
23 58F CAD VT-NS VT-NS
24 62M CAD VT-S VT-S (385)
25 34F PED VT-NS VT-NS
26 67M CM VT-S VT-S
'Discharged receiving cibenzoline; t Arrhythmia found on telemetry. 24 hour continuous electrocardiogram or electrophysiologic study; CAD =
coronary artery disease; CM = congestive cardiomyopathy; F = female; M = male; MVP = mitral valve prolapse; PED = primary electrical disease;
PVC = asymptomatic premature ventricular complexes; PVC-sx = symptomatic premature ventricular complexes; VF = ventricular fibrillation; VT-
NS = nonsustained ventricular tachycardia; VT-S = sustained ventricular tachycardia.
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Figure 2. Patient protocol. The numbers inside the rectangles
and circles represent the number of patients that underwent this
portion of the protocoL ECG = electrocardiogram; MUGA scan
= multigated technetium blood pool scan; q8h = every 8 hours,
Electrocardiographic monitoring. Arrhythmias were
monitored continuously during the entire study using a com-
puter-based telemetry system (Hewlett-Packard), The sys-
tem indicated premature ventricular complex trends and ep-
isodes of ventricular tachycardia defined as three or more
consecutive premature ventricular complexes. Each episode
of ventricular tachycardia was reviewed and confirmed by
an investigator. Daily scalar electrocardiograms at rest were
performed on each patient for measurement of spontaneous
cycle length and PR, QRS and QT intervals.
Three 24 hour continuous electrocardiographic record-
ings were performed during the control period and one re-
cording was performed during the second day of each dosage
level of cibenzoline. The recordings were analyzed (Cardio
Data Corporation) to determine hourly premature ventricular
complex frequency and the presence of ventricular tachycardia.
Continuous electrocardiographic recording was per-
formed using a two channel Avionics recorder (model 445B)
with computerized quantitation of premature ventricular
complexes using a template system (3). Reproducibility and
accuracy of premature ventricular complex quantitation have
been shown to be within 2%. Premature ventricular complex
frequency was expressed as the mean premature com-
plexes/h for a 24 hour period. For recordings lasting less
than 24 hours, the data were analyzed by determining the
mean premature ventricular complexes/h for the hours mon-
itored. All episodes of ventricular tachycardia were recorded
on hard copy and were confirmed by the primary investigator.
In comparing premature ventricular complex frequency
between 24 hour electrocardiographic recordings a change
in premature ventricular complex frequency of 83% or greater
was judged to be significant as derived from the analysis
by Morganroth et al. (4). Because these authors employed
a two-tailed t statistic to determine the range of spontaneous
variability of premature ventricular complex frequency, it
follows that both an increase and a decrease of 83% or more
represent a significant change in arrhythmia frequency. The
criteria of Velebit et al. (5) were also employed to determine
drug-induced aggravation of arrhythmia.
Multigated blood pool scans with technetium-labeled red
blood cells were performed in 12 patients during control
and at the maximal dose of cibenzoline for determination
of left ventricular ejection fraction.
Electrophysiologic studies. Electrophysiologic study was
performed in 25 of 26 patients during control state and
repeated in 10 patients while they received the maximal
dose of cibenzoline. For each study, patients were in the
postabsorptive, nonsedated state. Before the control elec-
trophysiologic study, all cardioactive medications were dis-
continued for a period exceeding 5 elimination half-lives of
the respective medications. During cibenzoline treatment,
the electrophysiologic study was repeated after patients re-
ceived at least 48 hours of maximal cibenzoline dosage.
Two or three multipolar electrode catheters were inserted
percutaneously and advanced to the heart under fluoroscopic
guidance. The catheters were positioned in the high lateral
right atrium, across the tricuspid valve in the region of the
His bundle and in the right ventricle.
Intracardiac electrograms and standard electrocardio-
graphic leads I, II, III and VI were displayed simultaneously
on a multichannel oscilloscope (Electronics for Medicine)
and recorded at paper speeds of75 to 150 mm/s. Intracardiac
and surface electrograms were recorded at frequencies of
30 to 500 and 0.1 to 20 Hz, respectively.
Pacing protocol. Pacing was performed using a pro-
grammable stimulator (MECA) that delivered square wave
stimuli of 2.0 ms duration at two times late diastolic thresh-
old. The following pacing protocol was used in an attempt
to initiate ventricular tachycardia:
I) High right atrial pacing was performed at progres-
sively faster rates until atrioventricular (AV) block occurred.
860 BROWNE ET AL.
CIBENZOLINE FOR VENTRICULAR ARRHYTHMIAS
lACC Vol. 3. No.3
March '984:857-64
2) Premature right atrial stimulation was performed at
two or more pacing cycle lengths. Premature stimuli were
introduced beginning late in diastole and at 10 to 20 ms
decrements until atrial refractoriness was obtained.
3) Premature right ventricular stimulation was per-
formed during sinus rhythm and ventricular pacing at cycle
lengths of 600, 500 and 400 ms. Premature stimuli (S2)
were initiated after every eighth paced or sinus complex
beginning in late diastole and the coupling interval was
progressively shortened until ventricular refractoriness was
reached. If ventricular tachycardia was not reproducibly
initiated, the shortest coupling interval (SIS2) resulting in
consistent ventricular capture was chosen. A second pre-
mature stimulus (S3) was then introduced beginning at an
S2S3 interval, which was 100 ms longer than the SIS2 in-
terval. The S2S3 interval was shortened by 10 to 20 ms
decrements until S3 no longer resulted in ventricular de-
polarization. If ventricular tachycardia was not reproducibly
induced, the S,52 interval was increased by 50 ms and the
S253 interval was set at 100 ms longer than the S I 52 interval.
The 52S3 interval was shortened until the ventricle was re-
fractory to 53, at which time the S,52 interval was decreased
by 10 ms until 53 again resulted in ventricular depolariza-
tion. This pacing sequence was repeated until the ventricle
was refractory to S2.
4) Three to eight complexes of right ventricular burst
pacing were initiated at a cycle length of 250 ms or more.
5) If ventricular tachycardia was not induced at the first
site tested. a second right ventricular pacing site was chosen
and programmed ventricular stimulation was repeated.
6) In one patient. three ventricular extrastimuli were used
(S25354) to induce ventricular tachycardia while pacing the
right ventricular apex.
Laboratory tests. These were performed to evaluate he-
patic, renal and hematologic function during the control
period and at each dose level. Trough plasma cibenzoline
concentrations were determined in seven patients during
maximal cibenzoline dosage and at end of each dosage
schedule.
Follow-up. Patients who were discharged receiving ci-
benzoline were followed up in an outpatient antiarrhythmic
drug clinic I month after discharge and every 3 months
thereafter. Interim history, physical examination, electro-
cardiogram at rest, laboratory tests of hepatic, renal and
hematologic function and a 24 hour continuous electrocar-
diogram were performed at each visit.
Statistical methods. Appropriate unpaired or paired Stu-
dent's t testing was performed on the data to evaluate the
statistical significance (6). Statistical significance was as-
signed to a probability (p) value less than 0.05.
Results
Overall outcome. Figure 3 diagrams the outcome of 26
patients who entered the study. The maximal dosage of
cibenzoline was 65 mg in 2 patients, 81.25 mg in 22 patients
and 97.5 mg in 2 patients. The dose was limited to 65 mg
in two patients because of a significant increase (>83%) in
premature ventricular complex frequency and in two other
patients the dose was increased to 97.5 mg because pre-
mature ventricular complex frequency was decreased at lower
dosage, but ventricular tachycardia was not completely sup-
pressed. In both of the latter patients, the higher dose failed
to prevent spontaneous ventricular tachycardia and one of
these patients had the new appearance of sustained ventric-
ular tachycardia that was thought to be drug related.
Cibenzoline was discontinued in 15 patients because it
failed to prevent spontaneous episodes of ventricular tachy-
cardia at the highest tested dose, in 4 patients because
cibenzoline failed to prevent ventricular tachycardia induc-
OVERALL OUTCOME
ENROLLMENT SYMPTOMATIC VENTRICULAR
ARRHYTHMIA
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Figure 3. Overall outcome for the 26 patients en-
rolled in the study of cibenzoline. EP = electro-
physiologic study; N = number of patients; Q8H
= every 8 hours; VT = ventricular tachycardia.
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Table 2. Scalar Electrocardiographic Data (ms)
Cibenzoline
Intervals (n) Control 65 mg 81.25 mg
PR (21) 170 ± 21 180 ± 26 193 ± 27
QRS (22) 100 ± 28 108 ± 32 117 ± 33
RR (22) 806 ± 116 791 ± 137 760 ± 97
QT (22) 395 ± 43 399 ± 39 404 ± 32
QTct (22) 443 ± 47 455 ± 61 467 ± 47
p
Value"
< 0.001
< 0.001
< 0.02
NS
< 0.05
"Student's paired t test comparing 81.25 mg dose with control. tCorrected by Bazett's formula (QT,. = QTrVRR).
HEMODYNAMIC EFFECTS OF CIBENZOLINE (N=12)
* SIGN IFICANTLY DECREASED (N=S)
Figure 4. Hemodynamic effects measured by multigated tech-
netium blood pool scanning (MUGA) for each patient before (left)
and during (right) cibenzoline therapy. There was no significant
change in the mean ejection fraction for the group of 12 patients
as represented by the solid bars. The asterisk (*) refers to a
significant decrease, that is, 5% or more in ejection fraction during
cibenzoline therapy compared with control. MAX. = maximal.
*
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maximal tolerated cibenzoline dosage while no ventricular
tachycardia was present in the other 8 patients. Of the six
patients who had no ventricular tachycardia during control
study, ventricular tachycardia was recorded in three patients
during maximal cibenzoline dosage and three patients con-
tinued to have no ventricular tachycardia.
The effect of cibenzoline on hourly premature ventricular
complex frequency (Fig. 5). Overall, mean hourly prema-
ture ventricular complex frequency did not significantly change
(mean 507 ± 521 to 350 ± 515 premature ventricular
complexes/h), but in 7 of 22 patients mean hourly premature
ventricular complex frequency decreased more than 83% at
maximal cibenzoline dosage compared with the control pe-
riod. Three patients exhibited a significant increase in pre-
tion at electrophysiologic study and in I patient because of
intolerable side effects. In six patients, cibenzoline was
continued for outpatient antiarrhythmic drug therapy at a
dose of 81.25 mg every 8 hours. Cibenzoline was judged
effective in these six patients because it prevented sponta-
neous nonsustained ventricular tachycardia in six and ven-
tricular tachycardia induction during electrophysiologic study
in three. One of the six patients did not undergo electro-
physiologic testing.
Scalar electrocardiographic data. The dose-related ef-
fects of cibenzoline on electrocardiographic intervals are
lited in Table 2. PR interval could not be measured in one
patient who had atrial fibrillation. PR, QRS, RR and cor-
rected QT interval by Bazett's formula increased slightly
but insignificantly during cibenzoline therapy in a dose-
related fashion.
Left ventricular function. No patient had worsening or
new onset of clinical signs or symptoms of congestive heart
failure during therapy with cibenzoline. There was no sig-
nificant change in mean ejection fraction during the control
period (0.39 ± 0.21) compared with that at the maximal
cibenioline dosage (0.36 ± 0.17) in the 12 patients who
had multigated blood pool scans at control and during max-
imal cibenzoline dosage (Fig. 4). However, ejection fraction
decreased by 5% or greater in five patients, increased by
5% or less in two patients and did not change in the re-
maining five patients. The heart rate at maximal cibenzoline
dose was within 10% of the control rate in 7 of the 12
patients. In the other five patients heart rate at rest increased
during cibenzoline therapy (mean 33 ± 16%, range 13 to
48) and three of these five patients had a significant decrease
in left ventricular ejection fraction.
Continuous electrocardiographic recording. During
the protocol, 22 patients had data from 24 hour continuous
electrocardiographic recordings performed at control and
during maximal cibenzoline dosage. Loss of the recording
data due to technical problems occurred in two patients and
cibenzoline therapy was terminated in two patients before
a recording could be obtained. The 72 hour control period
recordings disclosed that 16 patients had ventricular tachy-
cardia and six patients had no ventricular tachycardia. Of
the 16 patients who had ventricular tachycardia during con-
trol, 8 patients continued to have ventricular tachycardia at
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Table 3. Electrophysiologic Effects (in ms) of Cibenzoline in
10 Patients
* >83% DECREASE IN PVC IHR (N=7)
t >83% INCREASE IN PVC IHR (N=3)
CONTROL
3.5
3.0
-2.5
+
:!. 2.0
(l\
.2
a:
;: 1.5
U
>
0.
1.0
0.5
MAX. CIBENZOLINE DOSE
-
p
Control Cibenzoline Valuet
Sinus cycle length 774 ± 188 690 ± 125 NS
AH interval 80 ± 22 88 ± 18 NS
HV interval 53 ± 14 60 ± II < 0.07
Atrium
ERP 243 ± 28 239 ± 33 NS
FRP 276 ± 42 279 ± 33 NS
AV node
Max 1:1 CL 345 ± 70 348 ± 52 NS
ERP 285 ± 65 284 ± 35 NS
FRP 390 ± 56 389 ± 45 NS
RVapex
ERP 223 ± 16 241 ± 22 < 0.001
FRP 247 ± 18 264 ± 25 < 0,02
VT CL (n = 7)* 210 ± 31 260 ± 46 < 0.05
*Two patients had no inducible ventricular tachycardia while receiving
cibenzoline. One patient had no inducible ventricular tachycardia at control
study or while receiving cibenzoline. tStudenfs paired t test. AV =
atrioventricular; CL = cycle length; ERP = effective refractory period;
FRP = functional refractory period; Max I: I CL = the fastest rate at
which high right atrium could be paced and I: I AVconduction could be
maintained; RV = right ventricular; VT = ventricular tachycardia,
Figure 5. Effect of cibenzoline to reduce premature ventricular
complexes (PVC) is shown during the control period (left) and
during cibenzoline therapy (right) for the 22 patients who had
continuous electrocardiographic recording. There was no signifi-
cant change in the number of premature complexes per hour for
the overall study group (n == 22) as represented by the solid bars.
The ordinate represents the average hourly number of these com-
plexes over 72 hours during the control period and over 24 hours
during maximal cibenzoline therapy for each patient. The asterisks
(*) denote the seven patients with a greater than 83% decrease in
premature ventricular complexes per hour and the crosses (+)
denote the three patients with a greater than 83% increase in such
complexes per hour.
mature ventricular complex frequency defined as premature
ventricular complex increase of greater than 83% compared
with control values. One of the three patients had a 3-fold
increase in premature ventricular complex frequency and
developed spontaneous sustained ventricular tachycardia,
one patient had a 40-fold increase and one patient exhibited
a 4-fold increase in premature ventricular complex frequency.
Electrophysiologic effects. Twenty-five patients had an
electrophysiologic study during the control period and one
patient refused study. During maximal cibenzoline therapy
10 patients had a repeat electrophysiologic study, while
repeat electrophysiologic studies were not performed in the
other 15 patients because ventricular arrhythmias were judged
to have not improved or worsened in 14 patients and ci-
benzoline had been discontinued in I patient because of side
effects.
Table 3 summarizes the data from clinical electrophys-
iologic studies for the 10 patients who underwent electro-
physiologic study at control and maximal cibenzoline dos-
age. Of note, ventricular effective and functional refractory
periods prolonged significantly. In the patients who had
ventricular tachycardia induced at both studies, the ventric-
ular tachycardia cycle length prolonged significantly during
cibenzoline therapy.
Nine of the 10 patients had ventricular tachycardia in-
duced during the control electrophysiologic study. During
maximal cibenzoline therapy, ventricular tachycardia was
still induced in seven of the patients while cibenzoline pre-
vented induction of tachycardia in two patients. One patient
had no arrhythmia induced at control electrophysiologic study
or while receiving cibenzoline. Induction of ventricular
tachycardia was accomplished with two premature stimuli
during right ventricular apical pacing in all nine patients at
control electrophysiologic study. Of the seven patients who
had ventricular tachycardia induced during maximal ciben-
zoline therapy, five patients required two premature stimuli
during right ventricular apical pacing, one patient had ven-
tricular tachycardia induced with atrial pacing and one pa-
tient required three premature extrastimuli from the right
ventricular apex to induce ventricular tachycardia. There-
fore, ventricular tachycardia was more easily induced in one
patient, more difficult to induce in one patient and could
not be induced in two patients.
Side effects. Four patients had side effects that required
discontinuation of cibenzoline. In two patients, a significant
increase in premature ventricular complex frequency was
accompanied by worsened symptoms of palpitation , and one
patient developed sustained ventricular tachycardia that re-
lACC Vol. 3, No.3
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quired multiple cardioversions and disappeared only after 8
hours had elapsed from the last cibenzoline dose, One pa-
tient had nausea and abdominal pain and refused to continue
taking the drug, Of note, this patient had similar symptoms
with procainamide and quinidine, Two other patients ex-
perienced mild anticholinergic effects that consisted of blurred
vision and dry mouth, which did not require a change in
therapy, No patient exhibited any deterioration of hepatic,
renal or hematologic function, Plasma cibenzoline levels
ranged from 200 to 700 ng/ml in the seven patients who
had levels measured during maximal cibenzoline therapy
(Table 1),
Follow-up. Six patients were discharged receiving ci-
benzoline and three of them have continued cibenzoline
treatment during a mean follow-up period of 10 ± 4 months
(range 3 to 17), Of the six patients who were discharged
receiving cibenzoline, one patient was treated initially for
symptomatic premature ventricular complexes and five pa-
tients were treated for recurrent symptomatic nonsustained
ventricular tachycardia, The patient referred for sympto-
matic premature ventricular complexes had complete
suppression of three premature complexes on 24 hour con-
tinuous electrocardiographic recording at maximal ciben-
zoline dose and has remained symptom-free during the fol-
low-up period, Of the five patients treated for symptomatic
nonsustained ventricular tachycardia, two have remained
symptom-free, one died of cardiogenic shock occurring after
an acute myocardial infarction and two (both with ventric-
ular tachycardia during electrophysiologic study while re-
ceiving cibenzoline) have continued to experience palpita-
tion and had nonsustained ventricular tachycardia recorded
on continuous electrocardiographic monitoring, Both of these
patients have stopped taking cibenzoline,
Discussion
Clinical efficacy. Patients enrolled in the protocol can
be separated into two groups, Twelve patients (Group I)
had a history of sustained ventricular tachycardia or ven-
tricular fibrillation requiring cardioversion or defibrillation
and 14 patients (Group II) had a history of either sympto-
matic nonsustained ventricular tachycardia or frequent pre-
mature ventricular complexes, No patient in Group I had
an adequate antiarrhythmic response to cibenzoline, al-
though 3 of the 12 patients did exhibit complete suppression
of spontaneous ventricular tachycardia during telemetry and
continuous electrocardiographic recording, Two of these
three patients had sustained and one had nonsustained ven-
tricular tachycardia during electrophysiologic study while
receiving maximal cibenzoline therapy, In contrast, 4 of 14
patients in Group II were considered to have an adequate
antiarrhythmic response to cibenzoline and 7 (50%) of 14
exhibited no spontaneous ventricular tachycardia during te-
lemetry and continuous electrocardiographic recording,
The study group included only patients who had been
refractory to between two and seven other antiarrhythmic
drugs, The efficacy of any antiarrhythmic drug in this study
group would be expected to be limited, Because of this, the
value of cibenzoline in treating patients who have ventricular
arrhythmias that have not been refractory to other antiar-
rhythmic agents may be equal to or superior to that of
antiarrhythmic drugs currently available for clinical use,
Criteria and predictors of efficacy, Only 4 (15%) of the
26 patients enrolled in the protocol met two criteria of an-
tiarrhythmic efficacy, that is, suppression of spontaneous
ventricular tachycardia recorded by telemetry and contin-
uous electrocardiographic recording and prevention of ven-
tricular tachycardia induction at electrophysiologic study
during maximal cibenzoline therapy, If suppression of spon-
taneous ventricular tachycardia was the only criterion em-
ployed to determine successful therapy, then 7 (27%) of 26
patients would have been considered to have an adequate
antiarrhythmic regimen, Of these seven patients, two had
no ventricular tachycardia induced at electrophysiologic study,
were discharged receiving cibenzoline and have remained
asymptomatic during long-term therapy, In another two of
these seven patients, cibenzoline prevented spontaneous
ventricular tachycardia during continuous electrocardio-
graphic recording and telemetry, but ventricular tachycardia
was induced at electrophysiologic study during maximal
cibenzoline therapy, Both patients had symptomatic, non-
sustained ventricular tachycardia during follow-up and ci-
benzoline was discontinued, One other patient did not have
electrophysiologic testing and has continued cibenzoline long
term, In the remaining two patients, cibenzoline was dis-
continued after rapid sustained ventricular tachycardia was
induced during electrophysiologic study, Although the num-
ber of patients in the present study is small, it appears that
noninducibility during electrophysiologic study coupled with
no spontaneous ventricular tachycardia best predicted the
long-term efficacy of cibenzoline therapy,
Continuous electrocardiographic recording. In this
study we found that cibenzoline treatment decreased pre-
mature ventricular complex frequency by greater than 83%
in 7 of 22 patients, Only two of the seven patients were
from Group I, that is, patients who had sustained ventricular
tachycardia or ventricular fibrillation, while five patients
were from Group II, Therefore, using suppression of pre-
mature ventricular complexes as an indicator of antiar-
rhythmic effect, cibenzoline seemed to be more effective in
patients with symptomatic frequent premature ventricular
complexes or nonsustained ventricular tachycardia as com-
pared with patients who had sustained ventricular tachy-
cardia or ventricular fibrillation,
Suppression of premature ventricular complexes versus
ventricular tachycardia, For procainamide it has been re-
ported that the plasma concentration needed to suppress
ventricular tachycardia was lower than that needed to reduce
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significantly the premature ventricular complex frequency
(7). We examined this hypothesis in our 22 patients and
found that in 12 patients cibenzoline did not suppress ven-
tricular tachycardia or significantly reduce premature ven-
tricular complex frequency, while in 5 patients cibenzoline
suppressed spontaneous ventricular tachycardia and signif-
icantly reduced premature ventricular complex frequency.
In three patients, cibenzoline suppressed ventricular tachy-
cardia but did not significantly decrease premature ventric-
ular complex frequency. Of note, in the other two patients
cibenzoline significantly suppressed premature ventricular
complex frequency (93% and 92%, respectively) but spon-
taneous ventricular tachycardia was still present. Therefore,
it appears that in some patients a given plasma cibenzoline
concentration produced significant suppression of premature
ventricular complexes without suppressing ventricular
tachycardia and that significant suppression of premature
ventricular complexes alone does not accurately predict
suppression of ventricular tachycardia.
Hemodynamics. Although the mean left ventricular
ejection fraction did not change in our study patients, there
was a significant decrease in ejection fraction during ciben-
zoline therapy in 5 of 12 patients. In contrast with reports
on the hemodynamic effects of disopyramide (8), there is
much less depression of cardiac function produced by ci-
benzoline. No patient with a control ejection fraction less
than 40% had a decrease during cibenzoline treatment and
no patient developed clinical heart failure while receiving
cibenzoline.
Clinical electrophysiologic and electrocardiographic
data. There was a dosage-related increase in PR, QRS and
QT intervals. None of the changes were marked and no
patient developed heart block or an intraventricular con-
duction defect. In spite of significant prolongation of the
PR interval during cibenzoline therapy, neither AH nor HV
interval prolongation reached statistical significance. Pro-
longation of the PR interval reached significance because
of modest prolongation of the PA, AH and HV intervals.
Cibenzoline decreased spontaneous sinus cycle length,
which may reflect the vagolytic properties of the drug. There
was a modest prolongation of the right ventricular effective
(18 ± 22 ms) and functional (17 ± 25 ms) refractory
periods and an increase in cycle length of induced ventricular
tachycardia (50 ± 46 ms).
We evaluated the data obtained from the control elec-
trophysiologic study and found that no measured variable
or group of variables was predictive of antiarrhythmic drug
efficacy. Inability to induce ventricular tachycardia during
electrophysiologic study in patients receiving maximal ci-
benzoline therapy appeared to be an indicator of a favorable
long-term response.
Conclusion. Cibenzoline is a well-tolerated antiar-
rhythmic agent that effectively suppresses symptomatic ven-
tricular arrhythmias in some patients not successfully treated
with conventional antiarrhythmic drugs. In the patients in
this study, cibenzoline appeared to be reasonably effective
in those patients with symptomatic premature ventricular
complexes or nonsustained ventricular tachycardia but in-
effective in the patients with sustained ventricular tachy-
cardia or ventricular fibrillation.
We acknowledge Hoffmann-LaRoche Corporation for their analysis of
serum cibenzoline concentrations, Linda Richmond for her technical as-
sistance in data collection and Jill Cottengim for her help in preparation
of the manuscript.
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